SCHEMBL20548151

SCHEMBL20548151

ClCc1csc(N2CCCCCC2)n1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
AR P10275 1/20 0.49
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
DNM1L O00429 11/20 0.41
GFER P55789 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1436131 1.00 SMN1; SMN2 (0.49) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL8852641 0.98 SMN1; SMN2 (0.46) SMN1; SMN2ARTP53ALOX15HSD17B10
Hydrochloric Acid SCHEMBL7181442 0.96 SMN1; SMN2 (0.45) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL1436135 0.83 MAPT (0.59) SMN1; SMN2ARRAB9AMAPTMEN1
SCHEMBL7455543 0.83 AOC3 (0.49) HSD17B10RAB9AMAPTMEN1NPC1
SCHEMBL29518681 0.82 SMN1; SMN2 (0.49) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL10465680 0.82 SMN1; SMN2 (0.49) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL15356502 0.82 SMN1; SMN2 (0.50) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL23525581 0.80 SMN1; SMN2 (0.46) SMN1; SMN2ARTP53ALOX15HSD17B10
SCHEMBL10279631 0.80 OGA (0.48) SMN1; SMN2ARTP53ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168080-B2 Dynamin-1-like protein inhibitors MITOBRIDGE, INC. (US) 2021-11-09 US disclosed
US-11168080-B2 Dynamin-1-like protein inhibitors MITOBRIDGE, INC. (US) 2021-11-09 US disclosed
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-04-30 US disclosed
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-04-30 US disclosed
WO-2018200674-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS MITOBRIDGE, INC. (US) 2018-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168080-B2 Dynamin-1-like protein inhibitors DNM1L, DNM1, DNM2 SMN1; SMN2 2970/4885AR 4741/4885TP53 3749/4885
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS DNM1L, DNM1, DNM2 SMN1; SMN2 2970/4885AR 4741/4885TP53 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.